Incyte (INCY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 8, 2026, at Wilmington, Delaware, at 10:00 am ET.
Proxy materials and annual report for 2025 are available online for review and voting.
Shareholders can vote electronically until June 7, 2026, or request paper materials by May 28, 2026.
Voting matters and shareholder proposals
Election of eight directors to serve until the 2027 annual meeting.
Advisory vote to approve named executive officer compensation.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Board recommends voting FOR all nominees and proposals.
Board of directors and corporate governance
Eight director nominees listed for election, including Julian C. Baker and Jean-Jacques Bienaimé.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Incyte
- Diversifying portfolio and advancing late-stage assets to drive multi-billion dollar growth.INCY
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Acquisition brings a first-in-class VWD therapy with $1B+ sales potential and FDA Breakthrough status.INCY
M&A announcement8 Jun 2026 - CEO's sign-on award ties compensation to ambitious stock price targets; board urges approval.INCY
Proxy filing27 May 2026 - Phase III for CALR antibody 989 in ET launches mid-year, with major pipeline and market advances.INCY
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - Strong commercial growth and pipeline advances set the stage for sustained post-2029 momentum.INCY
Bank of America Global Healthcare Conference 202614 May 2026 - Multiple pivotal trials and product launches set to drive growth beyond Jakafi through 2030.INCY
Barclays 28th Annual Global Healthcare Conference11 May 2026 - Q1 2026 net sales rose 20% to $1.10B, with strong product and pipeline performance.INCY
Q1 202629 Apr 2026 - 2025 saw robust growth, pipeline advancement, and strong governance ahead of key shareholder votes.INCY
Proxy filing29 Apr 2026 - 2025 revenue up 21% to $5.14B, core business ex-Jakafi up 53%, with strong 2026 outlook.INCY
Q4 202511 Apr 2026